Libri di Roberto M. Lemoli

High-risk acute myeloblastic leukemia (HR AML) is charac­terized by unfavorable biologic and clinical features impairing the efficacy of conventional treatments resulting in less than 40% short-term complete remission (CR) rate and poor median overall survival (OS). In addition, high-risk disease occurs, often, in elderly patients with high comorbidity burden and these findings induce poor tolerability to chemotherapy and reduced eligibility to allogeneic stem cell transplantation (HSCT), the only curative therapeutic option in this setting. Here, leading experts in the field cover all the novel aspects concerning the updated definition, the diagnosis, the management and future perspectives tor HR AML patients. Over the last decade the great progress in molecular and cell biology, medicinal chemistry far drug design and immunology have resulted in the development and approval of a large number of novel therapeutics for patients with AML. Although the definition of HR AML is evolving, the better understanding of the genetic and biological characteristics of leukemic cells and their microenviroment will significantly contribute towards novel therapeutic approaches.